BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Adcirca (Tadalafil) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Adcirca (Tadalafil)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06290713-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT06290713)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: Vasodilator and Exercise
  Study for DMD (VASO-REx)\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06290713
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05206955-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05206955)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: Study of Tadalafil vs. P
 lacebo for Improving Hemodynamics and End-Organ Dysfunction in Fontan Phys
 iology\nEstimated primary completion: November 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05206955
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391579-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adcirca (Tadalafil): Phase 4 readout est. (NCT07391579)
DESCRIPTION:Adcirca (Tadalafil)\, phase 4.\nStudy: Daily Tadalafil 5 mg Com
 bined With On-Demand Sildenafil 100 mg for Treatment of Erectile Dysfuncti
 on in PDE-5I Non Responder Patients\nEstimated primary completion: Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0739157
 9
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05051436-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Adcirca (Tadalafil): Phase 4 readout est. (NCT05051436)
DESCRIPTION:Adcirca (Tadalafil)\, phase 4.\nStudy: The Effects of Mirabegro
 n and Tadalafil on Glucose Tolerance in Prediabetics\nEstimated primary co
 mpletion: January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/tadalafil#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05051436
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722884-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Adcirca (Tadalafil): Phase na readout est. (NCT07722884)
DESCRIPTION:Adcirca (Tadalafil)\, phase na.\nStudy: Tamsulosin Monotherapy 
 Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Mal
 e LUTS Secondary to BPH\nEstimated primary completion: 1 January 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07722884
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05179876-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05179876)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: A Study Providing Treatm
 ent Access in Participants With Pulmonary Hypertension Completing a Parent
  Study and Having no Other Option\nEstimated primary completion: 31 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517987
 6
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882901-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT07882901)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: Effects of Tadalafil on 
 Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitiv
 e Impairment\nEstimated primary completion: 20 February 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07882901
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753720-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Adcirca (Tadalafil): Phase 4 readout est. (NCT07753720)
DESCRIPTION:Adcirca (Tadalafil)\, phase 4.\nStudy: Daily Tadalafil as Adjun
 ctive Therapy Versus Monotherapy for PDE5 Inhibitor-Resistant Erectile Dys
 function\nEstimated primary completion: 30 June 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07753720
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844462-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Adcirca (Tadalafil): Phase 3 readout est. (NCT05844462)
DESCRIPTION:Adcirca (Tadalafil)\, phase 3.\nStudy: Tadalafil for Severe Pul
 monary Hypertension Due to Chronic Obstructive Pulmonary Disease\nEstimate
 d primary completion: October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tadalafil#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05844462
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654413-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Adcirca (Tadalafil): Phase 4 readout est. (NCT07654413)
DESCRIPTION:Adcirca (Tadalafil)\, phase 4.\nStudy: Tamsulosin With or Witho
 ut Tadalafil for Trial Without Catheter After Acute Urinary Retention Due 
 to Benign Prostatic Hyperplasia\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07654413
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07466030-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Adcirca (Tadalafil): Phase 1 readout est. (NCT07466030)
DESCRIPTION:Adcirca (Tadalafil)\, phase 1.\nStudy: Tadalafil 5 mg on Storag
 e Lower Urinary Tract Symptoms After Anatomical Endoscopic Enucleation of 
 the Prostate\nEstimated primary completion: 1 March 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07466030
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06968962-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Adcirca (Tadalafil): Phase na readout est. (NCT06968962)
DESCRIPTION:Adcirca (Tadalafil)\, phase na\, Pulmonary Arterial Hypertensio
 n.\nStudy: Comparison of Sequential to Initial Combination Therapy in PAH\
 nEstimated primary completion: May 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06968962
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172815-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT07172815)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: PDE5 Inhibitor for Alzhe
 imer's Disease\nEstimated primary completion: August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07172815
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07537855-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT07537855)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: Efficacy of Intracaverno
 sal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction\nEstimate
 d primary completion: September 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tadalafil#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07537855
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576335-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT07576335)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: Multimodal Prehabilitati
 on and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatect
 omy\nEstimated primary completion: 1 December 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tadalafil#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07576335
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05937854-518@assetmemo.bio
DTSTAMP:20261121T003110Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Adcirca (Tadalafil): Phase 2 readout est. (NCT05937854)
DESCRIPTION:Adcirca (Tadalafil)\, phase 2.\nStudy: Breathe Easier With Tada
 lafil Therapy for Dyspnea in COPD-PH\nEstimated primary completion: 1 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/tadalafil#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0593785
 4
URL:https://assetmemo.bio/drug/tadalafil#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
